EUVIMEDDescubrir EUVIMED
Open access

Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery

Jae W Lee, Chad A Komar, Fee Bengsch, Kathleen Graham, Gregory L Beatty

Current Protocols in Pharmacology · 2016-06 · 73 (1)

DOI: 10.1002/cpph.2 ↗

At a glance

Journal article in Current Protocols in Pharmacology, 2016-06. Written by Jae W Lee and 4 co-authors. Institution: Abramson Cancer Center; University of Pennsylvania, Philadelphia, Pennsylvania. Major MEDLINE topics: Animals, Genetically Modified, Carcinoma, Pancreatic Ductal, Disease Models, Animal, Mice. Cited 185 times so far (Crossref); 85 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIDDK NIH HHS.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer‐related deaths in the United States. For patients with unresectable disease, treatment options are limited and lack curative potential. Preclinical mouse models of PDAC that recapitulate the biology of human pancreatic cancer offer an opportunity for the rational development of novel treatment approaches that may improve patient outcomes. With the recent success of immunotherapy for subsets of patients with solid malignancies, interest is mounting in the possible use of immunotherapy for the treatment of PDAC. Considered in this unit is the value of genetic mouse models for characterizing the immunobiology of PDAC and for investigating novel immunotherapeutics. Several variants of these models are described, all of which may be used in drug development and for providing information on unique aspects of disease biology and therapeutic responsiveness. © 2016 by John Wiley & Sons, Inc.

Subjects

MeSH terms (MEDLINE)

Animals, Genetically ModifiedCarcinoma, Pancreatic DuctalDisease Models, AnimalMicePancreatic NeoplasmsAnimalsDrug DiscoveryHumansImmunotherapyMacrophagesT-Lymphocytes

Author keywords

KPCT cell exclusiongenetically engineered mouse modelimmunotherapyinflammationmacrophagepancreatic ductal adenocarcinoma

Authors and institutions

  • Abramson Cancer Center; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

  • NCI NIH HHS
  • NIDDK NIH HHS

Cite

APA

Lee, J. W., Komar, C. A., Bengsch, F., Graham, K., & Beatty, G. L. (2016). Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery. Current Protocols in Pharmacology, 73(1). https://doi.org/10.1002/cpph.2

Vancouver

Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery. Current Protocols in Pharmacology. 2016;73(1). doi:10.1002/cpph.2

BibTeX
@article{Lee2016,
  author = {Lee, Jae W and Komar, Chad A and Bengsch, Fee and Graham, Kathleen and Beatty, Gregory L},
  title = {Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery},
  journal = {Current Protocols in Pharmacology},
  year = {2016},
  volume = {73},
  number = {1},
  doi = {10.1002/cpph.2}
}
Start for free →